JFLLIFE - JFL Life

📊 NSE: JFLLIFE 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 8:37

💰 Financial Performance

Revenue Growth by Segment

Not disclosed in available documents. However, Profit Before Tax (PBT) for H1 FY26 stood at INR 3.65 Cr, which on an annualized basis (INR 7.30 Cr) represents a 19.05% increase over the FY25 PBT of INR 6.13 Cr.

Geographic Revenue Split

Not disclosed in available documents. Operations are concentrated in Ahmedabad, Gujarat, with manufacturing units at Unit-I (Ahmedabad) and Unit-II (Bavla).

Profitability Margins

Operating profit before working capital changes for H1 FY26 was INR 4.86 Cr. PBT margin trends show an upward trajectory with H1 FY26 PBT at INR 3.65 Cr compared to the full year FY25 of INR 6.13 Cr, indicating improved operational efficiency in the first half of the year.

EBITDA Margin

Not explicitly disclosed as a percentage. Operating profit before working capital changes was INR 4.86 Cr for H1 FY26. Finance costs stood at INR 0.68 Cr (14% of operating profit) and Depreciation at INR 0.53 Cr (11% of operating profit).

Capital Expenditure

Additions to property, plant, and equipment for H1 FY26 were INR 0.096 Cr. Total Non-Current Assets as of September 30, 2025, were INR 11.97 Cr, a slight decrease from INR 12.41 Cr in March 2025 due to depreciation.

Credit Rating & Borrowing

Total borrowings as of September 30, 2025, were INR 11.20 Cr, consisting of INR 10.93 Cr in short-term current borrowings and INR 0.27 Cr in long-term borrowings. Finance costs for H1 FY26 were INR 68.74 Lakhs.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents. The company operates in the life sciences/pharmaceutical sector, implying the use of Active Pharmaceutical Ingredients (APIs) and excipients.

Capacity Expansion

The company operates two manufacturing facilities: Unit-I at Ahmedabad and Unit-II at G.I.D.C. Kerala, Bavla, Ahmedabad. Specific MTPA or unit capacity figures were not disclosed.

Raw Material Costs

Not disclosed in available documents. However, inventories increased by 43% from INR 23.24 Cr in March 2025 to INR 33.23 Cr in September 2025, suggesting significant procurement activity.

📈 Strategic Growth

Expected Growth Rate

19%

Growth Strategy

The company is focusing on scaling its pharmaceutical manufacturing operations through its two units in Gujarat. The 43% increase in inventory (to INR 33.23 Cr) and 4.6% increase in trade receivables (to INR 36.55 Cr) suggest an aggressive push for market share and higher sales volumes in the upcoming quarters.

Products & Services

Pharmaceutical formulations and life sciences products manufactured at Unit-I and Unit-II.

Brand Portfolio

JFL Life Sciences.

🌍 External Factors

Industry Trends

The pharmaceutical industry is shifting toward higher compliance standards (Indian Accounting Standards/Ind AS) and more robust internal financial controls. JFLLIFE is positioning itself by maintaining unmodified audit opinions and complying with SEBI LODR regulations.

Competitive Moat

The company's moat is based on its established manufacturing infrastructure in Gujarat (Unit-I and Unit-II) and its compliance with corporate governance standards. However, high competition in the generic formulation space remains a challenge.

Macro Economic Sensitivity

The company is sensitive to healthcare spending and pharmaceutical regulatory changes in India, particularly in Gujarat where its units are located.

⚖️ Regulatory & Governance

Industry Regulations

The company complies with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It maintains a code of conduct for senior management and independent directors.

Taxation Policy Impact

The company paid INR 0.08 Lakhs in income tax during H1 FY26, compared to INR 102.39 Lakhs in FY25. Deferred tax liabilities stood at INR 31.61 Lakhs as of September 2025.

Legal Contingencies

The company reported no pending litigation as of March 31, 2025. There were no material foreseeable losses on long-term contracts or derivative contracts.